GeneReach Biotechnology (Taiwan) Insiders
| 4171 Stock | TWD 28.95 0.05 0.17% |
GeneReach Biotechnology employs about 16 people. The company is managed by 5 executives with a total tenure of roughly 38 years, averaging almost 7.0 years of service per executive, having 3.2 employees per reported executive. Recap of GeneReach Biotechnology's management performance can provide insight into the venture performance.
| Alison Lee Insider Chief Officer |
| Grace Chang Insider Chief Officer |
GeneReach |
GeneReach Biotechnology Management Team Effectiveness
The company has return on total asset (ROA) of 0.1319 % which means that it generated a profit of $0.1319 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3007 %, meaning that it generated $0.3007 on every $100 dollars invested by stockholders. GeneReach Biotechnology's management efficiency ratios could be used to measure how well GeneReach Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.GeneReach Biotechnology Workforce Comparison
GeneReach Biotechnology is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 1,146. GeneReach Biotechnology claims roughly 16.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.38 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.43 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.43. GeneReach Biotechnology Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. GeneReach Biotechnology Price Series Summation is a cross summation of GeneReach Biotechnology price series and its benchmark/peer.
GeneReach Biotechnology Notable Stakeholders
A GeneReach Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GeneReach Biotechnology often face trade-offs trying to please all of them. GeneReach Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GeneReach Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Alison Lee | Chief Officer | Profile | |
| Grace Chang | Chief Officer | Profile | |
| David Tsai | Chief Officer | Profile | |
| Simon Chung | Chief Officer | Profile | |
| Yuwen Huang | Deputy General Manager-Compliance & Production | Profile |
About GeneReach Biotechnology Management Performance
The success or failure of an entity such as GeneReach Biotechnology often depends on how effective the management is. GeneReach Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GeneReach management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GeneReach management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan. GENEREACH BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.
Please note, the imprecision that can be found in GeneReach Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GeneReach Biotechnology. Check GeneReach Biotechnology's Beneish M Score to see the likelihood of GeneReach Biotechnology's management manipulating its earnings.
GeneReach Biotechnology Workforce Analysis
Traditionally, organizations such as GeneReach Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GeneReach Biotechnology within its industry.GeneReach Biotechnology Manpower Efficiency
Return on GeneReach Biotechnology Manpower
| Revenue Per Employee | 63.3M | |
| Revenue Per Executive | 202.4M | |
| Net Income Per Employee | 23.5M | |
| Net Income Per Executive | 75.3M |
Additional Tools for GeneReach Stock Analysis
When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.